FDA Advisory Committees To Review KemPharm’s Abuse-Deterrent Drug Candidate Apadaz™
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- Wall Street ends down as oil prices, Treasury yields rise
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
KemPharm (KMPH) Receives Mixed FDA Panel Vote on Apadaz; Issues Commentary
May 5, 2016 5:17 PM EDTKemPharm, Inc. (Nasdaq: KMPH) announced that the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) reviewed and voted on Apadaz (benzhydrocodone hydrochloride and acetaminophen), KemPharms investigational abuse-deterrent product candidate for the short-term management of... More
